RecruitingNCT06753981
Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
Sponsor
Qianfoshan Hospital
Enrollment
48 participants
Start Date
Dec 10, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria2
- Consent and sign the informed consent form
- Non-low-risk PAH treatment-naive patients
Exclusion Criteria8
- Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension
- Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary
- Pregnant or lactating women
- Suffering from mental illness or cognitive impairment
- PAH patients with concurrent malignant tumors
- Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia
- Currently participating in other interventional clinical studies
- Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.
Interventions
DRUGEndothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06753981